The Role of the GP in the Management of Ambulatory Heart Failure

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05056649

Acronym

GPsHF

Enrollment

300

Registered

2021-09-24

Start date

2022-10-01

Completion date

2023-09-01

Last updated

2023-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Brief summary

To describe the causes mentioned by general practitioners, explaining the under-treatment of the three main treatments for heart failure with impaired ejection fraction (ARS blockers of the type ACEinhibitor/ARA2/ARNi, ß- and/or anti-aldosterone).

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

* Patients with a previous diagnosis of heart failure with impaired ejection fraction (LVEF \< 40%) * Under 85 years of age * Admitted to an Emergency department for cardiac decompensation * Hospitalized following this decompensation * Not deceased within one month of hospitalisation * Whose sum of the doses of ACEI or ARB2 + BB + aldosterone antagonist is less than 50% of the dose required for this patient\* (definition in annex) * Who did not object within one month of being informed

Exclusion criteria

- Patient objecting to the use of their data * Patient who is a minor * Patient who does not have a general practitioner

Design outcomes

Primary

Measure	Time frame
Quantitative analysis of verbatims after grouping	Through study completion, an average of 1 year

Countries

France

Contacts

Primary ContactJean-Marc BOIVIN, MD,PhD

jm.boivin@chru-nancy.fr3 83 15 73 11

Backup ContactNicolas GIRERD, MD, PhD

n.girerd@chru-nancy.fr383 5 7322

Outcome results